Abstract
The present invention relates to novel ecto-liposome fusion nanoparticles, and more specifically, provides novel stem cell-derived ecto-liposome fusion nanoparticles exhibiting superior targeting capability to a tumor site compared to conventional drug delivery carriers having targeting capability.
Full Text
What is claimed is:
The present invention relates to novel ecto-liposome fusion nanoparticles, and more specifically, provides novel stem cell-derived ecto-liposome fusion nanoparticles exhibiting superior targeting capability to a tumor site compared to conventional drug delivery carriers having targeting capability.
Timeline
Filed
05/08/2026Published
09/10/2026Granted
Not AvailableIPC Codes(11)
A61K 9/127:Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/175:having the group N—C(O)—N=N— or e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
A61K 31/196:the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil